Jonasch, Eric <br/><br/>
Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Sep 2009 
 - 4076-81 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2008.21.3660  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--administration & dosage<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bevacizumab<br/>Carcinoma, Renal Cell--drug therapy<br/>Chemotherapy, Adjuvant<br/>Disease-Free Survival<br/>Erlotinib Hydrochloride<br/>Feasibility Studies<br/>Female<br/>Humans<br/>Kaplan-Meier Estimate<br/>Kidney Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Neoadjuvant Therapy<br/>Nephrectomy<br/>Proportional Hazards Models<br/>Prospective Studies<br/>Quinazolines--administration & dosage<br/>Risk Assessment<br/>Time Factors<br/>Treatment Outcome<br/>Wound Healing--drug effects